| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Departments of Pathology [D. R. S., R. W., Y. Z., D. M. D., H. R., T. J. G., E. R. F., K. R. C.], Internal Medicine [K. R. C., E. R. F.], Pediatrics and Communicable Diseases [R. K., D. E. M., S. M. H.], Biostatistics [J. M. G. T.], Epidemiology [S. L. R. K.], and Statistics [K. A. S., G. M.], The University of Michigan, Ann Arbor, Michigan. 48109, and Department of Pathology, Weill Medical College of Cornell University, New York, New York, 10021 [L. H. E.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
OvCa is a morphologically and biologically heterogeneous disease, which has likely contributed to difficulties in defining the molecular alterations associated with its development and progression. On the basis of morphological criteria, there are four major types of primary ovarian adenocarcinomas (serous, mucinous, endometrioid, and clear cell). The serous adenocarcinomas comprise about one-half of all OvCas and almost always present as stage III or IV disease (1)
. The endometrioid adenocarcinomas, which account for 
20–25% of OvCas, have also typically spread beyond the ovary at the time of diagnosis (1)
. Hence, the majority of poor prognosis (high stage) OvCas exhibit either serous or endometrioid differentiation. Clear cell and mucinous adenocarcinomas are less common, each accounting for fewer than 10% of all OvCas. Most of the mucinous and over one-half of the clear cell adenocarcinomas are confined to the ovaries at presentation (1
, 4)
. However, a number of studies have noted a particularly unfavorable prognosis for the clear cell carcinomas, even when corrected for tumor stage (5, 6, 7)
. In fact, in current clinical practice, all clear cell OvCas are treated as high-grade (grade 3) neoplasms (8)
.
Some molecular studies have offered support for the notion that the different histological types of OvCas likely represent distinct disease entities [reviewed by Feeley and Wells (9) and Aunoble et al. (10) ]. For example, serous adenocarcinomas demonstrate frequent p53 gene mutations, and upwards of 85% of mucinous ovarian adenocarcinomas show K-ras gene mutations. Endometrioid adenocarcinomas preferentially exhibit microsatellite instability and mutations of CTNNB1 (ß-catenin). Moreover, studies using comparative genomic hybridization have shown a divergence of DNA copy number changes in serous, mucinous, and endometrioid OvCas (11) . Notably, very little is known about the molecular pathobiology of clear cell carcinoma. Taken together, these data suggest that the various histological types of OvCa, although presumably originating from the ovarian surface epithelium or related cell types such as endometriosis, represent histopathologically, genetically, and biologically distinct diseases. Understanding the molecular basis of each morphological type and its biological behavior should eventually lead to the development of more specific and effective treatments for ovarian cancer.
Recent studies have offered preliminary data on gene expression profiles of OvCas and/or derivative cell lines (12, 13, 14, 15, 16, 17) . Although these studies have provided some useful insights, issues such as small sample size, exclusive analysis of cell lines, or focus on a single histological type of OvCa are shortcomings. To define the molecular signatures of OvCa, analysis of a large number of OvCas representing all major types is needed. In the present study, oligonucleotide microarrays were used to profile and compare gene expression patterns in 113 fresh frozen OvCa specimens. We establish that gene expression patterns in OvCa reflect both morphology and biological behavior. Moreover, clear cell OvCa has a distinctive pattern of gene expression that distinguishes it from other poor-prognosis OvCas.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
RNA Isolation, cRNA Synthesis, and Gene Expression Profiling.
Primary tumor tissues were manually microdissected before RNA extraction to ensure that each tumor sample contained at least 70% neoplastic cells. Total RNA was extracted from frozen tissue biopsies with Trizol (Life Technologies, Inc., Carlsbad, CA), then further purified using RNeasy spin columns (Qiagen, Valencia, CA) according to the manufacturers’ protocols. High-density oligonucleotide microarrays [HuGeneFL arrays (7129 probe sets); Affymetrix, Santa Clara, CA] were used in this study. The preparation of cRNA, hybridization, and scanning of the microarrays were performed according to the manufacturer’s protocols, as reported previously (19)
.
Data Processing.
Each probe set on the HuGeneFL microarray typically consists of 20 coordinated pairs of oligonucleotides. Within a probe pair, one probe is perfectly complementary (perfect match,) whereas the other probe (mismatch) is identical to the complementary probe except for an altered central base. To obtain an expression measure for a given probe set, the mismatch hybridization values were subtracted from the perfect match values, and the average of the middle 50% of these differences was used as the expression measure for that probe set. In this study, we analyzed 7069 non-control probe sets, each of which represents a human transcript. A quantile normalization procedure was performed to adjust for differences in the probe intensity distribution across different chips. Briefly, we applied a monotone linear spline to each chip that mapped quantiles 0.01 up to 0.99 (in increments of 0.01) exactly to the corresponding quantiles of a standard chip. The transform log2[200 + max(X;0)] was then applied.4
Statistical Analysis.
A PCA of the log-transformed data was used to provide a visual depiction of the variation in gene expression (20)
. The PCA identifies a set of statistically independent projections, or components, of the expression data. The first PC captures the greatest fraction of the overall variance in tumor gene expression compared with any other projection. The second PC captures the greatest fraction of variance subject to being independent of the first projection, and so on. Using any two PCs, a pair of coordinates can be determined for each sample. These coordinates can be used to construct a two-dimensional view that reflects the relative locations of tumors in the higher-dimensional space. A pair of tumors that fall close together have more similar gene expression values than a pair of tumors that fall farther apart. Using LDA (20)
, we also examined linear combinations of k PCs at a time (k = 2–100) to find the two-dimensional view of the data that provided the best separation between all of the histological types. Notably, the results of a PCA are completely dependent on the selection of genes for use in the procedure. We performed one PCA using 7069 probe sets to examine the breadth of molecular differences between morphological types. An elliptic region was determined for each histological type such that 95% of future observations are expected to fall within the region. These regions were computed under bivariate normality for the PC scores and with the PC axes held fixed. A second, more focused, PCA was conducted using histological type-specific markers identified as described below.
Specific markers for a given histological type were selected as those genes that were more than 2-fold overexpressed in the given type compared with each of the other three types, considered separately, and that had a t test P of <0.01 (one group versus all others pooled). Differential gene expression between groups was quantified based on differences between group averages in the log-transformed data. A randomization procedure was used to verify that there were far more genes satisfying these criteria than would be found by chance alone. We then built a classifier out of the p genes that were identified as specific to a particular histological type using a "five nearest-neighbor with majority voting" classification rule (21) . A leave-one-out cross-validation was used to estimate the error rate of this classifier. One tumor was set aside at a time, and the remaining 103 tumors were used to identify the k type-specific genes. This set of genes was then used to predict the histological type of the sample that was held out. This procedure was repeated 104 times, with each sample being held out exactly once.
q-RT-PCR.
q-RT-PCR was used to validate differential expression of selected genes in RNA samples from primary OvCas. We used 10 tumors from each type, including 31 tumors (8 serous, 7 endometrioid, 9 mucinous, and 7 clear cell) from the group of 113 analyzed on the microarrays. q-RT-PCR was performed with an ABI Prism 7700 Sequence Analyzer using the manufacturer’s recommended protocol (PE Applied Biosystems, Foster City, CA). Each reaction was run in duplicate. q-RT-PCR reactions for target and internal control genes were performed in separate tubes. The comparative threshold cycle (CT) method was used for the calculation of amplification fold as specified by the manufacturer. The forward (f) and reverse (r) primers and probe (p) for each gene validated by q-RT-PCR and for HPRT, which served as an internal control, are available on the web site specified above. Differences among histological types in the q-RT-PCR expression data were tested using the Kruskal-Wallis nonparametric test. Pearson product-moment correlations were used to estimate the degree of association between the microarray and q-RT-PCR data.
TMAs and Immunohistochemistry.
An OvCa TMA was constructed for this study (22)
. All arrayed tissues were selected from the Surgical Pathology archives of the University of Michigan Health System. The TMA block contains three representative cores from each of 69 OvCa specimens (26 serous, 22 endometrioid, 10 mucinous, and 11 clear cell). Eight of the 69 carcinomas in the TMA (2 mucinous, 1 endometrioid, and 5 serous) were included in the group of 113 carcinomas subjected to gene expression profiling; the remainder represents an independent set of tumors. TMA sections were immunohistochemically stained as previously described (23)
, with anti-WT1 antibody (C-19, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and anti-pS2 (anti-TFF1) antibody (NCL-pS2, Novocastra Laboratories, United Kingdom) at dilutions of 1:500 and 1:600, respectively. Immunoreactivity for WT1 and TFF1 was interpreted independently by three observers (Y. Z., R. W., and T. J. G.). The results were scored on the basis of cytoplasmic staining intensity for TFF1 (-, no staining; +, weak; ++, moderate; +++, strong), and the percentage of positive nuclei for WT1 (-, no positive cells; ±, <5%; +, 6–25%; ++, 26–50%; +++, 51–75%; ++++, >75%).
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. Fig. 1
shows scatterplots of the first two PCs that were computed using 7069 probe sets on the microarray. Only the 104 primary OvCa specimens showing a single type of differentiation (i.e., not of mixed histology), were used for this analysis. The mucinous and clear cell OvCas were readily distinguished from the serous OvCas, regardless of tumor stage and grade (Fig. 1)
. In contrast, the endometrioid OvCas showed significant overlap with all of the other types. The high-stage (III, IV) tumors were largely separable from the low-stage (I, II) tumors based on their gene expression profiles, which indicated that gene expression patterns reflect the biological behavior of OvCas (Fig. 1B)
. Similar separation was noted between the low-grade (1)
and high-grade (2
, 3)
OvCas, particularly when clear cell carcinomas are excluded (Fig. 1C)
. Notably, most of the endometrioid OvCas grouping with the serous OvCas were high stage (III or IV) and/or high grade, whereas the low-stage/grade endometrioid tumors showed greater similarity to the mucinous and/or clear cell tumors. Even in this global analysis, the clear cell carcinomas had a gene expression signature that was clearly distinct from the other poor-prognosis OvCas (i.e., the serous and high-stage/grade endometrioid carcinomas).
|
|
. In contrast, it took at least 40 PCs to strongly separate the mucinous group, and 97 PCs to strongly separate the endometrioid group (distinctive, but overlapping patterns corresponding to mucinous, endometrioid, and serous OvCa are already visible using 9 PCs). We decided to use 9 PCs because leave-one-out cross-validation studies indicated the first 9 PCs had a greater proportion of variance explained, and estimated using cross-validation, than was expected by chance, and because 9 PCs reproducibly distinguishes between the clear cell tumors and other subtypes. Moreover, we did another type of cross-validation in which both the PCs and the optimal LDA components were reestimated with each tumor held out, after which we recreated the scatterplot of PC scores for all of the tumors (analogous to Fig. 1D
). When nine PCs were used, all eight of the clear cell samples, when held out, projected much closer to the other seven clear cell samples than to any other sample. The full PCA, LDA, and cross-validation results are available on the web site specified in "Materials and Methods." The rather striking separation between morphological types reflects our finding that there are significant numbers of mean gene expression differences between types: specifically, 905 clear cell, 373 endometrioid, 1100 mucinous, and 1443 serous t test differences at P < 0.01 (one type versus others pooled).
Clear Cell OvCas Have a Distinctive Gene Expression Signature.
To identify a set of histological-type-specific genes, we selected those genes that were at least 2-fold increased in one tumor type compared with each of the others (considered separately) and had a t test P of <0.01. We found 172 probe sets representing 158 unique genes (19 serous, 2 endometrioid, 64 mucinous, and 73 clear cell) that satisfied our criteria. In this analysis, the number of genes identified for each tumor type is itself a measure of how distinctive the gene expression signature is for a given histological type. Hence, clear cell carcinomas displayed the most distinctive gene expression profile, whereas the gene expression profile of endometrioid carcinomas was the least distinctive. A randomization procedure was used to assess how many genes were likely to satisfy our criteria by chance alone. The histological type labels were randomly permuted across the 104 samples belonging to the four histological types, and the number of genes in the randomized data that satisfied the above criteria was determined. This process was repeated independently 1000 times. We summarize these values using: (median, 95th percentile, maximum) for each histological type as follows. For clear cell OvCa, 73 type-specific genes were identified compared with (2, 9, 34) in the randomized data. For serous OvCa, 18 genes met our criteria compared with (0, 0, 3) in the randomized data. For mucinous OvCa, 64 genes met our criteria compared with (1, 7, 31) in the randomized data. Note that none of the 1000 randomized data sets had as many markers as the actual data.
A PCA of the 158 type-specific genes was used to examine how well a set of targeted markers distinguishes between histological types of OvCa and to visualize these differences in gene expression (Fig. 2)
. This PCA view is similar to those in Fig. 1
, but shows more distinct separation of the tumor types. Note that clear cell carcinoma is nonoverlapping with any other type. In contrast, although serous and mucinous types are clearly set apart from each other, the endometrioid samples invade the characteristic regions of both types. Using these 158 genes, we developed a classifier and performed a leave-one-out cross-validation. We found that only 1 of the 8 clear cell carcinomas was misclassified (as endometrioid) and no tumors were misclassified as clear cell. Interestingly, both clear cell and endometrioid adenocarcinomas are often associated with endometriosis, which may serve as a common precursor to both tumor types (9)
.
|
. These genes can be grouped into broad functional categories and they include known and potential targets for OvCa therapy, as well as a number of candidate clear-cell specific diagnostic markers. All 158 up-regulated as well as 2-fold down-regulated genes in each of the histological types are provided as supplemental data on the web site specified in "Materials and Methods."
|
. Not unexpectedly, the tumors with mixed differentiation displayed a gene expression profile akin to the dominant component in the specimen actually profiled.
Validation of Microarray Data.
We used q-RT-PCR assays to validate the microarray data. Three genes differentially expressed among the different tumor types (FXYD2, TFF1, and WT1) were selected for q-RT-PCR analysis. A comparison of the microarray and q-RT-PCR data for these three genes is shown in Fig. 3
. Expression differences between tumor types for TFF1 (P = 0.0002), FXYD2 (P < 0.0001), and WT1 (P = 0.0002) were readily apparent. Moreover, for all three of the genes, the q-RT-PCR data were highly correlated (P < 0.0001) to the microarray data (r = 0.91, 0.79, and 0.51, respectively), as estimated from the 31 samples included in both the q-RT-PCR and microarray experiments. The q-RT-PCR data mirror the microarray data, both qualitatively and quantitatively, and suggest that most array probe sets are likely to accurately measure the levels of the intended transcript within a complex mixture of transcripts.
|
.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The observation that endometrioid OvCas do not exhibit a very distinctive gene expression pattern highlights limitations of using morphology alone to classify tumors. Poorly differentiated OvCas can be difficult to classify into morphological categories, and our findings indicate that many of the high-grade endometrioid OvCas are indistinguishable from the serous OvCas based on their gene expression profile. The PCA using virtually all of the genes represented on the oligonucleotide microarray suggests that the clear cell OvCas are more similar to a subset of mucinous and endometrioid carcinomas than they are to serous carcinomas. This may reflect mounting evidence that clear cell, endometrioid, and mucinous adenocarcinomas likely arise from metaplastic Müllerian epithelium (e.g., endometriosis, endomucinosis, or benign mucinous neoplasms) rather than directly from the ovarian surface epithelium, which is more likely the case for the serous carcinomas (9) .
The different histological types of OvCa are currently treated as though they represent a single disease. However, because molecular defects appear to differ among the most common types of OvCa, suspicion was aroused that OvCa represents a group of distinct, albeit related, diseases (9 , 10) . Our study offers additional persuasive support for the genetic diversity of these neoplasms, as reflected by their gene expression profiles. Recognition of such diversity should allow therapeutic approaches to be better tailored to the characteristics of each tumor type. In previous work, we have shown that adenocarcinomas from three different organs (lung, colon, and ovary) exhibit organ-specific gene expression profiles, although all are gland-forming epithelial tumors with substantial histopathological resemblance to one another (19) . Not surprisingly, the clinical management of these tumors varies depending on the site of tumor origin. Interestingly, the OvCas showed more heterogeneity than do adenocarcinomas of the lung or colon, which suggests that gene expression profiling might further separate OvCas into biologically and clinically meaningful subgroups. Our current study provides support for the notion that the poor-prognosis OvCas can indeed be separated into different groups based on their gene expression signatures, with clear cell OvCas showing the most distinctive gene expression profile. Our identification of a number of clear cell-specific markers lays the groundwork for future studies testing some of these biomarkers for clinical utility in the diagnosis and, eventually perhaps, the treatment of clear cell OvCa.
A sizeable number of genes preferentially overexpressed in clear cell, compared with other histological types of OvCa, have been identified through our analysis. At least some of these may prove to be useful diagnostic markers for clear cell OvCa. For example, GPX3 (glutathione peroxidase 3), has been previously reported as a clear cell OvCa marker (24) . FXYD2 (FXYD domain-containing ion transport regulator 2) and RBP4 (retinol binding protein 4), are over 20-fold up-regulated in clear cell carcinomas compared with the other tumor types and are also promising candidates for clear cell-specific markers. The overexpression of certain types of genes in clear cell OvCas may also provide insights into their disproportionately poor prognosis relative to other types of OvCa. With respect to this hypothesis, glutathione peroxidase 3 (GPX3), glutaredoxin (GLRX), and superoxide dismutase (SOD2) have all been implicated in oxidative stress response and particularly high levels of these and perhaps other antioxidant proteins in clear cell OvCas may render these tumors more resistant to chemotherapy (25) . Overexpression of these genes in clear cell carcinomas provides support for the notion that antioxidant inhibitors, in combination with standard chemotherapy, may improve treatment response of this aggressive type of OvCa (24 , 25) . Notably, ERB-B2/HER-2/NEU was also found to be differentially up-regulated in clear cell OvCa. This gene encodes the target for the humanized anti-HER2/neu antibody, trastuzumab (Herceptin), that is showing promise for treatment of patients with ovarian cancers showing overexpression of Her-2/neu protein (26) .
The idea that carcinomas arising from one organ, yet exhibiting different types of differentiation, might be distinct clinicopathological entities is certainly not a new one. Indeed, pathologists have long held the view that OvCas can be broadly classified into biologically meaningful categories based on their morphological appearance. Nonetheless, as suggested by this study, global gene expression profiling can be a useful adjunct to the morphology-based OvCa classification schemes currently used, allowing the identification of useful diagnostic and prognostic markers, as well as type-specific therapeutic targets.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported by funds from the National Cancer Institute, NIH (U19 CA84953 and RO1 CA94172) and from the Department of Defense (DAMD 17-1-1-0727), and in part by the Tissue Core of the University of Michigan Comprehensive Cancer Center (P30 CA46952). 
2 To whom requests for reprints should be addressed, at Department of Pathology, University of Michigan Medical School, 4301 MSRB III, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0638. Phone: (734) 764-1549; Fax: (734) 647-7979; E-mail: kathcho{at}umich.edu
3 The abbreviations used are: OvCa, ovarian carcinoma; NCCN, National Comprehensive Cancer Network; FIGO, International Federation of Gynecologists and Obstetricians; PC, principal component; PCA, PC analysis; TMA, tissue microarray; LDA, linear discriminant analysis; q-RT-PCR, quantitative reverse-transcription-PCR.
4 A more detailed description of the methods, as well as the freely available code, can be found at http://dot.ped.med.umich.edu:2000/pub/Ovary/index.html.
Received 4/17/02. Accepted 6/20/02.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  A. Berchuck, E. S. Iversen, J. Luo, J. P. Clarke, H. Horne, D. A. Levine, J. Boyd, M. A. Alonso, A. A. Secord, M. Q. Bernardini, et al. Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome Clin. Cancer Res., April 1, 2009; 15(7): 2448 - 2455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Tothill, A. V. Tinker, J. George, R. Brown, S. B. Fox, S. Lade, D. S. Johnson, M. K. Trivett, D. Etemadmoghadam, B. Locandro, et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome Clin. Cancer Res., August 15, 2008; 14(16): 5198 - 5208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Iorio, R. Visone, G. Di Leva, V. Donati, F. Petrocca, P. Casalini, C. Taccioli, S. Volinia, C.-G. Liu, H. Alder, et al. MicroRNA Signatures in Human Ovarian Cancer Cancer Res., September 15, 2007; 67(18): 8699 - 8707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Evelyn, S. M. Wade, Q. Wang, M. Wu, J. A. Iniguez-Lluhi, S. D. Merajver, and R. R. Neubig CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling Mol. Cancer Ther., August 1, 2007; 6(8): 2249 - 2260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. N. Fehrmann, X.-y. Li, A. G. J. van der Zee, S. de Jong, G. J. te Meerman, E. G. E. de Vries, and A. P. G. Crijns Profiling Studies in Ovarian Cancer: A Review Oncologist, August 1, 2007; 12(8): 960 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M El-Naggar, M. T Malik, A. Martin, J. P Moore, M. Proctor, T. Hamid, and S. S Kakar Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptor-pituitary tumor transforming gene transgenic mice J. Endocrinol., July 1, 2007; 194(1): 179 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Schwartz, K. Moin, B. Yao, L. M. Matrisian, L. M. Coussens, T. H. Bugge, B. Fingleton, H. B. Acuff, M. Sinnamon, H. Nassar, et al. Hu/Mu ProtIn Oligonucleotide Microarray: Dual-Species Array for Profiling Protease and Protease Inhibitor Gene Expression in Tumors and Their Microenvironment Mol. Cancer Res., May 1, 2007; 5(5): 443 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S P Tan and S. Kaye Ovarian clear cell adenocarcinoma: a continuing enigma J. Clin. Pathol., April 1, 2007; 60(4): 355 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Itamochi, J. Kigawa, Y. Kanamori, T. Oishi, C. Bartholomeusz, R. Nahta, F. J. Esteva, N. Sneige, N. Terakawa, and N. T. Ueno Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy Mol. Cancer Ther., January 1, 2007; 6(1): 227 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Bamias, Z Yu, P. Weinberger, S Markakis, D Kowalski, R. Camp, D. Rimm, M. Dimopoulos, and A Psyrri Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with {beta}-catenin levels and outcome in patients with epithelial ovarian cancer Ann. Onc., December 1, 2006; 17(12): 1797 - 1802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Denkert, J. Budczies, T. Kind, W. Weichert, P. Tablack, J. Sehouli, S. Niesporek, D. Konsgen, M. Dietel, and O. Fiehn Mass Spectrometry-Based Metabolic Profiling Reveals Different Metabolite Patterns in Invasive Ovarian Carcinomas and Ovarian Borderline Tumors. Cancer Res., November 15, 2006; 66(22): 10795 - 10804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Castellano, J. F. Reid, P. Alberti, M. L. Carcangiu, A. Tomassetti, and S. Canevari New Potential Ligand-Receptor Signaling Loops in Ovarian Cancer Identified in Multiple Gene Expression Studies Cancer Res., November 15, 2006; 66(22): 10709 - 10719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Lorenzi, W. C. Reinhold, M. Rudelius, M. Gunsior, U. Shankavaram, K. J. Bussey, U. Scherf, G. S. Eichler, S. E. Martin, K. Chin, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells Mol. Cancer Ther., November 1, 2006; 5(11): 2613 - 2623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. DiFeo, G. Narla, J. Hirshfeld, O. Camacho-Vanegas, J. Narla, S. L. Rose, T. Kalir, S. Yao, A. Levine, M. J. Birrer, et al. Roles of KLF6 and KLF6-SV1 in Ovarian Cancer Progression and Intraperitoneal Dissemination. Clin. Cancer Res., June 15, 2006; 12(12): 3730 - 3739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, J. Huang, N. Yang, S. Liang, A. Barchetti, A. Giannakakis, M. G. Cadungog, A. O'Brien-Jenkins, M. Massobrio, K. F. Roby, et al. Integrative Genomic Analysis of Protein Kinase C (PKC) Family Identifies PKC{iota} as a Biomarker and Potential Oncogene in Ovarian Carcinoma. Cancer Res., May 1, 2006; 66(9): 4627 - 4635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Hendrix, R. Wu, R. Kuick, D. R. Schwartz, E. R. Fearon, and K. R. Cho Fibroblast Growth Factor 9 Has Oncogenic Activity and Is a Downstream Target of Wnt Signaling in Ovarian Endometrioid Adenocarcinomas Cancer Res., February 1, 2006; 66(3): 1354 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, R. Wu, K. R. Cho, K. A. Shedden, T. J. Barder, and D. M. Lubman Classification of Cancer Cell Lines Using an Automated Two-dimensional Liquid Mapping Method with Hierarchical Clustering Techniques Mol. Cell. Proteomics, January 1, 2006; 5(1): 43 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Avril, S. Sassen, B. Schmalfeldt, J. Naehrig, S. Rutke, W. A. Weber, M. Werner, H. Graeff, M. Schwaiger, and W. Kuhn Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer J. Clin. Oncol., October 20, 2005; 23(30): 7445 - 7453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tsuda, Y. M. Ito, Y. Ohashi, K.-K. Wong, Y. Hashiguchi, W. R. Welch, R. S. Berkowitz, M. J. Birrer, and S. C. Mok Identification of Overexpression and Amplification of ABCF2 in Clear Cell Ovarian Adenocarcinomas by cDNA Microarray Analyses Clin. Cancer Res., October 1, 2005; 11(19): 6880 - 6888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Zorn, T. Bonome, L. Gangi, G. V.R. Chandramouli, C. S. Awtrey, G. J. Gardner, J. C. Barrett, J. Boyd, and M. J. Birrer Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer Clin. Cancer Res., September 15, 2005; 11(18): 6422 - 6430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Marquez, K. A. Baggerly, A. P. Patterson, J. Liu, R. Broaddus, M. Frumovitz, E. N. Atkinson, D. I. Smith, L. Hartmann, D. Fishman, et al. Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon Clin. Cancer Res., September 1, 2005; 11(17): 6116 - 6126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Eder, X. Sui, D. G. Rosen, L. K Nolden, K. W. Cheng, J. P. Lahad, M. Kango-Singh, K. H. Lu, C. L. Warneke, E. N. Atkinson, et al. Atypical PKC{iota} contributes to poor prognosis through loss of apical-basal polarity and Cyclin E overexpression in ovarian cancer PNAS, August 30, 2005; 102(35): 12519 - 12524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mor, I. Visintin, Y. Lai, H. Zhao, P. Schwartz, T. Rutherford, L. Yue, P. Bray-Ward, and D. C. Ward Serum protein markers for early detection of ovarian cancer PNAS, May 24, 2005; 102(21): 7677 - 7682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Santin, S. Cane, S. Bellone, M. Palmieri, E. R. Siegel, M. Thomas, J. J. Roman, A. Burnett, M. J. Cannon, and S. Pecorelli Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin Cancer Res., May 15, 2005; 65(10): 4334 - 4342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Berchuck, E. S. Iversen, J. M. Lancaster, J. Pittman, J. Luo, P. Lee, S. Murphy, H. K. Dressman, P. G. Febbo, M. West, et al. Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers Clin. Cancer Res., May 15, 2005; 11(10): 3686 - 3696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Shedden, M. P. Kshirsagar, D. R. Schwartz, R. Wu, H. Yu, D. E. Misek, S. Hanash, H. Katabuchi, L. H. Ellenson, E. R. Fearon, et al. Histologic Type, Organ of Origin, and Wnt Pathway Status: Effect on Gene Expression in Ovarian and Uterine Carcinomas Clin. Cancer Res., March 15, 2005; 11(6): 2123 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Hartmann, K. H. Lu, G. P. Linette, W. A. Cliby, K. R. Kalli, D. Gershenson, R. C. Bast, J. Stec, N. Iartchouk, D. I. Smith, et al. Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy Clin. Cancer Res., March 15, 2005; 11(6): 2149 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Morrison, W. Farrar, J. Kneile, N. Williams, Y. Liu-Stratton, A. Bakaletz, M. A. Aldred, and C. Eng Molecular Classification of Parathyroid Neoplasia by Gene Expression Profiling Am. J. Pathol., August 1, 2004; 165(2): 565 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Rhodes, J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, T. Barrette, A. Pandey, and A. M. Chinnaiyan Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression PNAS, June 22, 2004; 101(25): 9309 - 9314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Lu, A. P. Patterson, L. Wang, R. T. Marquez, E. N. Atkinson, K. A. Baggerly, L. R. Ramoth, D. G. Rosen, J. Liu, I. Hellstrom, et al. Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis Clin. Cancer Res., May 15, 2004; 10(10): 3291 - 3300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Terasawa, S. Sagae, M. Toyota, K. Tsukada, K. Ogi, A. Satoh, H. Mita, K. Imai, T. Tokino, and R. Kudo Epigenetic Inactivation of TMS1/ASC in Ovarian Cancer Clin. Cancer Res., March 15, 2004; 10(6): 2000 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, G. Yang, J. A. Thompson-Lanza, A. Glassman, K. Hayes, A. Patterson, R. T. Marquez, N. Auersperg, Y. Yu, W. C. Hahn, et al. A Genetically Defined Model for Human Ovarian Cancer Cancer Res., March 1, 2004; 64(5): 1655 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Schmalbach, D. B. Chepeha, T. J. Giordano, M. A. Rubin, T. N. Teknos, C. R. Bradford, G. T. Wolf, R. Kuick, D. E. Misek, D. K. Trask, et al. Molecular Profiling and the Identification of Genes Associated With Metastatic Oral Cavity/Pharynx Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, March 1, 2004; 130(3): 295 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Li, M. Cuilleron, A. Gentil-Perret, M. Cottier, K. Passebosc-Faure, C. Lambert, C. Genin, and J. Tostain Rapid and Sensitive Detection of Messenger RNA Expression for Molecular Differential Diagnosis of Renal Cell Carcinoma Clin. Cancer Res., December 15, 2003; 9(17): 6441 - 6446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tsuchiya, M. Sakamoto, J. Yasuda, M. Chuma, T. Ohta, M. Ohki, T. Yasugi, Y. Taketani, and S. Hirohashi Expression Profiling in Ovarian Clear Cell Carcinoma: Identification of Hepatocyte Nuclear Factor-1{beta} as a Molecular Marker and a Possible Molecular Target for Therapy of Ovarian Clear Cell Carcinoma Am. J. Pathol., December 1, 2003; 163(6): 2503 - 2512. [Abstract] [Full Text]
|
|
|
|
|
|
K. A. Shedden, J. M. G. Taylor, T. J. Giordano, R. Kuick, D. E. Misek, G. Rennert, D. R. Schwartz, S. B. Gruber, C. Logsdon, D. Simeone, et al. Accurate Molecular Classification of Human Cancers Based on Gene Expression Using a Simple Classifier with a Pathological Tree-Based Framework Am. J. Pathol., November 1, 2003; 163(5): 1985 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Reed, J. J. Yu, A. Davies, J. Gannon, and S. L. Armentrout Clear Cell Tumors Have Higher mRNA Levels of ERCC1 and XPB Than Other Histological Types of Epithelial Ovarian Cancer Clin. Cancer Res., November 1, 2003; 9(14): 5299 - 5305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Schaner, D. T. Ross, G. Ciaravino, T. Sorlie, O. Troyanskaya, M. Diehn, Y. C. Wang, G. E. Duran, T. L. Sikic, S. Caldeira, et al. Gene Expression Patterns in Ovarian Carcinomas Mol. Biol. Cell, November 1, 2003; 14(11): 4376 - 4386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Zorn, A. A. Jazaeri, C. S. Awtrey, G. J. Gardner, S. C. Mok, J. Boyd, and M. J. Birrer Choice of Normal Ovarian Control Influences Determination of Differentially Expressed Genes in Ovarian Cancer Expression Profiling Studies Clin. Cancer Res., October 15, 2003; 9(13): 4811 - 4818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Schwartz, R. Wu, S. L. R. Kardia, A. M. Levin, C.-C. Huang, K. A. Shedden, R. Kuick, D. E. Misek, S. M. Hanash, J. M. G. Taylor, et al. Novel Candidate Targets of {beta}-Catenin/T-cell Factor Signaling Identified by Gene Expression Profiling of Ovarian Endometrioid Adenocarcinomas Cancer Res., June 1, 2003; 63(11): 2913 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hirasawa, F. Saito-Ohara, J. Inoue, D. Aoki, N. Susumu, T. Yokoyama, S. Nozawa, J. Inazawa, and I. Imoto Association of 17q21-q24 Gain in Ovarian Clear Cell Adenocarcinomas with Poor Prognosis and Identification of PPM1D and APPBP2 as Likely Amplification Targets Clin. Cancer Res., June 1, 2003; 9(6): 1995 - 2004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wu, L. Lin, D. G. Beer, L. H. Ellenson, B. J. Lamb, J.-M. Rouillard, R. Kuick, S. Hanash, D. R. Schwartz, E. R. Fearon, et al. Amplification and Overexpression of the L-MYC Proto-Oncogene in Ovarian Carcinomas Am. J. Pathol., May 1, 2003; 162(5): 1603 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Singer, R. Oldt III, Y. Cohen, B. G. Wang, D. Sidransky, R. J. Kurman, and I.-M. Shih Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma J Natl Cancer Inst, March 19, 2003; 95(6): 484 - 486. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
